Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
Jonathan I. Silverberg, Anna M. Tallman, William C. Ports, Robert A. Gerber, Huaming Tan, Michael A. Zielinski
Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis pools results from 2 phase 3 studies (ClinicalTrials.gov, NCT02118766 [AD-301]; NCT02118792 [AD-302]) to evaluate crisaborole efficacy in patients ≥ 2 years with mild-to-moderate atopic dermatitis (per Investigator’s Static Global Assessment) using the Atopic Dermatitis Severity Index (ADSI) and percentage of treatable body surface area (%BSA). Patients were randomly assigned 2:1 to receive crisaborole (n = 1,016) or vehicle (n = 506) twice daily for 28 days. ADSI scores were the sum of pruritus, erythema, exudation, excoriation, and lichenification severity scores, each graded on a 4-point scale from none (0) to severe (3). Respective mean changes in ADSI score and %BSA at day 29 were (crisaborole vs. vehicle) −3.52 versus −2.42 (p < 0.0001) and –7.43 versus –4.44 (p < 0.0001). Crisaborole was effective in treating mild-to-moderate atopic dermatitis based on ADSI and %BSA.
Crisaborole is a nonsteroidal topical treatment for mild-to-moderate atopic dermatitis. In 2 large, identically designed phase 3 studies of patients with mild-to-moderate atopic dermatitis, significantly more patients treated with crisaborole achieved treatment success per the Investigator’s Static Global Assessment (ISGA) than patients treated with vehicle. This post hoc analysis confirms the effectiveness of crisaborole in alleviating atopic dermatitis severity using the measures Atopic Dermatitis Severity Index (ADSI) and percentage of treatable body surface area (%BSA).